Damien Noone1,2, Rae S M Yeung3,4,5, Diane Hebert6,3. 1. Division of Nephrology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. damien.noone@sickkids.ca. 2. Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. damien.noone@sickkids.ca. 3. Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. 4. Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada. 5. Department of Immunology, University of Toronto, Toronto, Ontario, Canada. 6. Division of Nephrology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.
Abstract
OBJECTIVES: Data on kidney transplant outcomes for pediatric patients with end-stage renal disease (ESRD) secondary to anti-neutrophil cytoplasmic antibody glomerulonephritis (ANCA GN), particularly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), is limited. We describe our experience of kidney transplantation in pediatric ANCA GN patients. METHODS: We performed a retrospective review of patients with ANCA GN who developed ESRD and were transplanted at a single center between the years 2000 and 2014. RESULTS: Since 2000, there were seven pediatric patients with ANCA GN (four MPA) transplanted. Mean age at ANCA GN diagnosis was 11.8 ± 2.8 (range, 7.2-15.4) years. All seven were ANCA (three anti-PR3/four anti-MPO) positive. Estimated glomerular filtration rate (eGFR) at diagnosis was 11.7 ± 6.3 ml/min/1.73 m2. All received steroids and cyclophosphamide and three (23.3%) received plasma exchange. Six were dialysis dependent by 6 months post diagnosis. Time from diagnosis to transplant was 30 ± 12 (range, 17-48) months. Six of the seven received a deceased donor transplant. All patients received induction therapy and standard maintenance immunosuppression post transplant. Median duration of follow-up post transplantation was 27 months (range, 13-88 months). Median eGFR at last follow-up was 77 ml/min/1.73 m2 (range, 7.9-83.5). One patient lost her transplant to acute cellular rejection following non-adherence to immunosuppression after 21 months of stable transplant function. No patient had recurrence of vasculitis, either renal or extra-renal. CONCLUSIONS: Short-term patient and allograft survival in pediatric patients with ESRD secondary to ANCA GN seems excellent, with no recurrence of vasculitis post transplant in this small cohort.
OBJECTIVES: Data on kidney transplant outcomes for pediatric patients with end-stage renal disease (ESRD) secondary to anti-neutrophil cytoplasmic antibody glomerulonephritis (ANCA GN), particularly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), is limited. We describe our experience of kidney transplantation in pediatric ANCA GN patients. METHODS: We performed a retrospective review of patients with ANCA GN who developed ESRD and were transplanted at a single center between the years 2000 and 2014. RESULTS: Since 2000, there were seven pediatric patients with ANCA GN (four MPA) transplanted. Mean age at ANCA GN diagnosis was 11.8 ± 2.8 (range, 7.2-15.4) years. All seven were ANCA (three anti-PR3/four anti-MPO) positive. Estimated glomerular filtration rate (eGFR) at diagnosis was 11.7 ± 6.3 ml/min/1.73 m2. All received steroids and cyclophosphamide and three (23.3%) received plasma exchange. Six were dialysis dependent by 6 months post diagnosis. Time from diagnosis to transplant was 30 ± 12 (range, 17-48) months. Six of the seven received a deceased donor transplant. All patients received induction therapy and standard maintenance immunosuppression post transplant. Median duration of follow-up post transplantation was 27 months (range, 13-88 months). Median eGFR at last follow-up was 77 ml/min/1.73 m2 (range, 7.9-83.5). One patient lost her transplant to acute cellular rejection following non-adherence to immunosuppression after 21 months of stable transplant function. No patient had recurrence of vasculitis, either renal or extra-renal. CONCLUSIONS: Short-term patient and allograft survival in pediatric patients with ESRD secondary to ANCA GN seems excellent, with no recurrence of vasculitis post transplant in this small cohort.
Authors: Nishkantha Arulkumaran; Susan Jawad; Stuart W Smith; Lorraine Harper; Paul Brogan; Charles D Pusey; Alan D Salama Journal: Pediatr Rheumatol Online J Date: 2011-06-19 Impact factor: 3.054
Authors: Arda Göçeroğlu; Chinar Rahmattulla; Annelies E Berden; Marlies E J Reinders; Ron Wolterbeek; Eric J Steenbergen; Luuk B Hilbrands; Iris Noorlander; Stefan P Berger; Carine J Peutz-Kootstra; Maarten H L Christiaans; Marcory C R F van Dijk; Anoek A E de Joode; Roel Goldschmeding; Arjan D van Zuilen; Lorraine Harper; Mark A Little; E Christiaan Hagen; Jan A Bruijn; Ingeborg M Bajema Journal: Transplantation Date: 2016-04 Impact factor: 4.939
Authors: Annelies E Berden; Franco Ferrario; E Christiaan Hagen; David R Jayne; J Charles Jennette; Kensuke Joh; Irmgard Neumann; Laure-Hélène Noël; Charles D Pusey; Rüdiger Waldherr; Jan A Bruijn; Ingeborg M Bajema Journal: J Am Soc Nephrol Date: 2010-07-08 Impact factor: 10.121
Authors: Pavla Dolezalova; Fiona E Price-Kuehne; Seza Özen; Susanne M Benseler; David A Cabral; Jordi Anton; Jürgen Brunner; Rolando Cimaz; Katheleen M O'Neil; Carol A Wallace; Nicholas Wilkinson; Despina Eleftheriou; Erkan Demirkaya; Marek Böhm; Petra Krol; Raashid A Luqmani; Paul A Brogan Journal: Ann Rheum Dis Date: 2012-10-25 Impact factor: 19.103